Global Parkinsons Disease Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Parkinsons Disease Drug market size was valued at USD 5651 million in 2023 and is forecast to a readjusted size of USD 7494.1 million by 2030 with a CAGR of 4.1% during review period.
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Parkinsons Disease Drug industry chain, the market status of Hospital (Carbidopa/Levodopa, Dopamine Receptor Agonists), Clinics (Carbidopa/Levodopa, Dopamine Receptor Agonists), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Parkinsons Disease Drug.
Regionally, the report analyzes the Parkinsons Disease Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Parkinsons Disease Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Parkinsons Disease Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Parkinsons Disease Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Doses), revenue generated, and market share of different by Type (e.g., Carbidopa/Levodopa, Dopamine Receptor Agonists).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Parkinsons Disease Drug market.
Regional Analysis: The report involves examining the Parkinsons Disease Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Parkinsons Disease Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Parkinsons Disease Drug:
Company Analysis: Report covers individual Parkinsons Disease Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Parkinsons Disease Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinics).
Technology Analysis: Report covers specific technologies relevant to Parkinsons Disease Drug. It assesses the current state, advancements, and potential future developments in Parkinsons Disease Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Parkinsons Disease Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Parkinsons Disease Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Parkinsons Disease Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Parkinsons Disease Drug, with price, sales, revenue and global market share of Parkinsons Disease Drug from 2019 to 2024.
Chapter 3, the Parkinsons Disease Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Parkinsons Disease Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Parkinsons Disease Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Parkinsons Disease Drug.
Chapter 14 and 15, to describe Parkinsons Disease Drug sales channel, distributors, customers, research findings and conclusion.
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Parkinsons Disease Drug industry chain, the market status of Hospital (Carbidopa/Levodopa, Dopamine Receptor Agonists), Clinics (Carbidopa/Levodopa, Dopamine Receptor Agonists), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Parkinsons Disease Drug.
Regionally, the report analyzes the Parkinsons Disease Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Parkinsons Disease Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Parkinsons Disease Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Parkinsons Disease Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Doses), revenue generated, and market share of different by Type (e.g., Carbidopa/Levodopa, Dopamine Receptor Agonists).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Parkinsons Disease Drug market.
Regional Analysis: The report involves examining the Parkinsons Disease Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Parkinsons Disease Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Parkinsons Disease Drug:
Company Analysis: Report covers individual Parkinsons Disease Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Parkinsons Disease Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinics).
Technology Analysis: Report covers specific technologies relevant to Parkinsons Disease Drug. It assesses the current state, advancements, and potential future developments in Parkinsons Disease Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Parkinsons Disease Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Parkinsons Disease Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Carbidopa/Levodopa
- Dopamine Receptor Agonists
- MAO-Inhibitors
- Hospital
- Clinics
- Other
- Teva
- Novartis AG
- GSK
- AbbVie
- Merck
- Boehringer Ingelheim
- Impax Laboratories
- Lundbeck
- Sun Pharma
- Wockhardt
- UCB
- Bausch Health
- Acadia
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Parkinsons Disease Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Parkinsons Disease Drug, with price, sales, revenue and global market share of Parkinsons Disease Drug from 2019 to 2024.
Chapter 3, the Parkinsons Disease Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Parkinsons Disease Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Parkinsons Disease Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Parkinsons Disease Drug.
Chapter 14 and 15, to describe Parkinsons Disease Drug sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Parkinsons Disease Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Parkinsons Disease Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Carbidopa/Levodopa
1.3.3 Dopamine Receptor Agonists
1.3.4 MAO-Inhibitors
1.4 Market Analysis by Application
1.4.1 Overview: Global Parkinsons Disease Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinics
1.4.4 Other
1.5 Global Parkinsons Disease Drug Market Size & Forecast
1.5.1 Global Parkinsons Disease Drug Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Parkinsons Disease Drug Sales Quantity (2019-2030)
1.5.3 Global Parkinsons Disease Drug Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Teva
2.1.1 Teva Details
2.1.2 Teva Major Business
2.1.3 Teva Parkinsons Disease Drug Product and Services
2.1.4 Teva Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Teva Recent Developments/Updates
2.2 Novartis AG
2.2.1 Novartis AG Details
2.2.2 Novartis AG Major Business
2.2.3 Novartis AG Parkinsons Disease Drug Product and Services
2.2.4 Novartis AG Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Novartis AG Recent Developments/Updates
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Parkinsons Disease Drug Product and Services
2.3.4 GSK Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 GSK Recent Developments/Updates
2.4 AbbVie
2.4.1 AbbVie Details
2.4.2 AbbVie Major Business
2.4.3 AbbVie Parkinsons Disease Drug Product and Services
2.4.4 AbbVie Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 AbbVie Recent Developments/Updates
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business
2.5.3 Merck Parkinsons Disease Drug Product and Services
2.5.4 Merck Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Merck Recent Developments/Updates
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Parkinsons Disease Drug Product and Services
2.6.4 Boehringer Ingelheim Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Boehringer Ingelheim Recent Developments/Updates
2.7 Impax Laboratories
2.7.1 Impax Laboratories Details
2.7.2 Impax Laboratories Major Business
2.7.3 Impax Laboratories Parkinsons Disease Drug Product and Services
2.7.4 Impax Laboratories Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Impax Laboratories Recent Developments/Updates
2.8 Lundbeck
2.8.1 Lundbeck Details
2.8.2 Lundbeck Major Business
2.8.3 Lundbeck Parkinsons Disease Drug Product and Services
2.8.4 Lundbeck Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Lundbeck Recent Developments/Updates
2.9 Sun Pharma
2.9.1 Sun Pharma Details
2.9.2 Sun Pharma Major Business
2.9.3 Sun Pharma Parkinsons Disease Drug Product and Services
2.9.4 Sun Pharma Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Sun Pharma Recent Developments/Updates
2.10 Wockhardt
2.10.1 Wockhardt Details
2.10.2 Wockhardt Major Business
2.10.3 Wockhardt Parkinsons Disease Drug Product and Services
2.10.4 Wockhardt Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Wockhardt Recent Developments/Updates
2.11 UCB
2.11.1 UCB Details
2.11.2 UCB Major Business
2.11.3 UCB Parkinsons Disease Drug Product and Services
2.11.4 UCB Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 UCB Recent Developments/Updates
2.12 Bausch Health
2.12.1 Bausch Health Details
2.12.2 Bausch Health Major Business
2.12.3 Bausch Health Parkinsons Disease Drug Product and Services
2.12.4 Bausch Health Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Bausch Health Recent Developments/Updates
2.13 Acadia
2.13.1 Acadia Details
2.13.2 Acadia Major Business
2.13.3 Acadia Parkinsons Disease Drug Product and Services
2.13.4 Acadia Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Acadia Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PARKINSONS DISEASE DRUG BY MANUFACTURER
3.1 Global Parkinsons Disease Drug Sales Quantity by Manufacturer (2019-2024)
3.2 Global Parkinsons Disease Drug Revenue by Manufacturer (2019-2024)
3.3 Global Parkinsons Disease Drug Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Parkinsons Disease Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Parkinsons Disease Drug Manufacturer Market Share in 2023
3.4.2 Top 6 Parkinsons Disease Drug Manufacturer Market Share in 2023
3.5 Parkinsons Disease Drug Market: Overall Company Footprint Analysis
3.5.1 Parkinsons Disease Drug Market: Region Footprint
3.5.2 Parkinsons Disease Drug Market: Company Product Type Footprint
3.5.3 Parkinsons Disease Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Parkinsons Disease Drug Market Size by Region
4.1.1 Global Parkinsons Disease Drug Sales Quantity by Region (2019-2030)
4.1.2 Global Parkinsons Disease Drug Consumption Value by Region (2019-2030)
4.1.3 Global Parkinsons Disease Drug Average Price by Region (2019-2030)
4.2 North America Parkinsons Disease Drug Consumption Value (2019-2030)
4.3 Europe Parkinsons Disease Drug Consumption Value (2019-2030)
4.4 Asia-Pacific Parkinsons Disease Drug Consumption Value (2019-2030)
4.5 South America Parkinsons Disease Drug Consumption Value (2019-2030)
4.6 Middle East and Africa Parkinsons Disease Drug Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
5.2 Global Parkinsons Disease Drug Consumption Value by Type (2019-2030)
5.3 Global Parkinsons Disease Drug Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
6.2 Global Parkinsons Disease Drug Consumption Value by Application (2019-2030)
6.3 Global Parkinsons Disease Drug Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
7.2 North America Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
7.3 North America Parkinsons Disease Drug Market Size by Country
7.3.1 North America Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
7.3.2 North America Parkinsons Disease Drug Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
8.2 Europe Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
8.3 Europe Parkinsons Disease Drug Market Size by Country
8.3.1 Europe Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
8.3.2 Europe Parkinsons Disease Drug Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Parkinsons Disease Drug Market Size by Region
9.3.1 Asia-Pacific Parkinsons Disease Drug Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Parkinsons Disease Drug Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
10.2 South America Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
10.3 South America Parkinsons Disease Drug Market Size by Country
10.3.1 South America Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
10.3.2 South America Parkinsons Disease Drug Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Parkinsons Disease Drug Market Size by Country
11.3.1 Middle East & Africa Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Parkinsons Disease Drug Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Parkinsons Disease Drug Market Drivers
12.2 Parkinsons Disease Drug Market Restraints
12.3 Parkinsons Disease Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Parkinsons Disease Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Parkinsons Disease Drug
13.3 Parkinsons Disease Drug Production Process
13.4 Parkinsons Disease Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Parkinsons Disease Drug Typical Distributors
14.3 Parkinsons Disease Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Parkinsons Disease Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Parkinsons Disease Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Carbidopa/Levodopa
1.3.3 Dopamine Receptor Agonists
1.3.4 MAO-Inhibitors
1.4 Market Analysis by Application
1.4.1 Overview: Global Parkinsons Disease Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinics
1.4.4 Other
1.5 Global Parkinsons Disease Drug Market Size & Forecast
1.5.1 Global Parkinsons Disease Drug Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Parkinsons Disease Drug Sales Quantity (2019-2030)
1.5.3 Global Parkinsons Disease Drug Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Teva
2.1.1 Teva Details
2.1.2 Teva Major Business
2.1.3 Teva Parkinsons Disease Drug Product and Services
2.1.4 Teva Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Teva Recent Developments/Updates
2.2 Novartis AG
2.2.1 Novartis AG Details
2.2.2 Novartis AG Major Business
2.2.3 Novartis AG Parkinsons Disease Drug Product and Services
2.2.4 Novartis AG Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Novartis AG Recent Developments/Updates
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Parkinsons Disease Drug Product and Services
2.3.4 GSK Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 GSK Recent Developments/Updates
2.4 AbbVie
2.4.1 AbbVie Details
2.4.2 AbbVie Major Business
2.4.3 AbbVie Parkinsons Disease Drug Product and Services
2.4.4 AbbVie Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 AbbVie Recent Developments/Updates
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business
2.5.3 Merck Parkinsons Disease Drug Product and Services
2.5.4 Merck Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Merck Recent Developments/Updates
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Parkinsons Disease Drug Product and Services
2.6.4 Boehringer Ingelheim Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Boehringer Ingelheim Recent Developments/Updates
2.7 Impax Laboratories
2.7.1 Impax Laboratories Details
2.7.2 Impax Laboratories Major Business
2.7.3 Impax Laboratories Parkinsons Disease Drug Product and Services
2.7.4 Impax Laboratories Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Impax Laboratories Recent Developments/Updates
2.8 Lundbeck
2.8.1 Lundbeck Details
2.8.2 Lundbeck Major Business
2.8.3 Lundbeck Parkinsons Disease Drug Product and Services
2.8.4 Lundbeck Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Lundbeck Recent Developments/Updates
2.9 Sun Pharma
2.9.1 Sun Pharma Details
2.9.2 Sun Pharma Major Business
2.9.3 Sun Pharma Parkinsons Disease Drug Product and Services
2.9.4 Sun Pharma Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Sun Pharma Recent Developments/Updates
2.10 Wockhardt
2.10.1 Wockhardt Details
2.10.2 Wockhardt Major Business
2.10.3 Wockhardt Parkinsons Disease Drug Product and Services
2.10.4 Wockhardt Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Wockhardt Recent Developments/Updates
2.11 UCB
2.11.1 UCB Details
2.11.2 UCB Major Business
2.11.3 UCB Parkinsons Disease Drug Product and Services
2.11.4 UCB Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 UCB Recent Developments/Updates
2.12 Bausch Health
2.12.1 Bausch Health Details
2.12.2 Bausch Health Major Business
2.12.3 Bausch Health Parkinsons Disease Drug Product and Services
2.12.4 Bausch Health Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Bausch Health Recent Developments/Updates
2.13 Acadia
2.13.1 Acadia Details
2.13.2 Acadia Major Business
2.13.3 Acadia Parkinsons Disease Drug Product and Services
2.13.4 Acadia Parkinsons Disease Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Acadia Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PARKINSONS DISEASE DRUG BY MANUFACTURER
3.1 Global Parkinsons Disease Drug Sales Quantity by Manufacturer (2019-2024)
3.2 Global Parkinsons Disease Drug Revenue by Manufacturer (2019-2024)
3.3 Global Parkinsons Disease Drug Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Parkinsons Disease Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Parkinsons Disease Drug Manufacturer Market Share in 2023
3.4.2 Top 6 Parkinsons Disease Drug Manufacturer Market Share in 2023
3.5 Parkinsons Disease Drug Market: Overall Company Footprint Analysis
3.5.1 Parkinsons Disease Drug Market: Region Footprint
3.5.2 Parkinsons Disease Drug Market: Company Product Type Footprint
3.5.3 Parkinsons Disease Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Parkinsons Disease Drug Market Size by Region
4.1.1 Global Parkinsons Disease Drug Sales Quantity by Region (2019-2030)
4.1.2 Global Parkinsons Disease Drug Consumption Value by Region (2019-2030)
4.1.3 Global Parkinsons Disease Drug Average Price by Region (2019-2030)
4.2 North America Parkinsons Disease Drug Consumption Value (2019-2030)
4.3 Europe Parkinsons Disease Drug Consumption Value (2019-2030)
4.4 Asia-Pacific Parkinsons Disease Drug Consumption Value (2019-2030)
4.5 South America Parkinsons Disease Drug Consumption Value (2019-2030)
4.6 Middle East and Africa Parkinsons Disease Drug Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
5.2 Global Parkinsons Disease Drug Consumption Value by Type (2019-2030)
5.3 Global Parkinsons Disease Drug Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
6.2 Global Parkinsons Disease Drug Consumption Value by Application (2019-2030)
6.3 Global Parkinsons Disease Drug Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
7.2 North America Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
7.3 North America Parkinsons Disease Drug Market Size by Country
7.3.1 North America Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
7.3.2 North America Parkinsons Disease Drug Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
8.2 Europe Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
8.3 Europe Parkinsons Disease Drug Market Size by Country
8.3.1 Europe Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
8.3.2 Europe Parkinsons Disease Drug Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Parkinsons Disease Drug Market Size by Region
9.3.1 Asia-Pacific Parkinsons Disease Drug Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Parkinsons Disease Drug Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
10.2 South America Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
10.3 South America Parkinsons Disease Drug Market Size by Country
10.3.1 South America Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
10.3.2 South America Parkinsons Disease Drug Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Parkinsons Disease Drug Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Parkinsons Disease Drug Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Parkinsons Disease Drug Market Size by Country
11.3.1 Middle East & Africa Parkinsons Disease Drug Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Parkinsons Disease Drug Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Parkinsons Disease Drug Market Drivers
12.2 Parkinsons Disease Drug Market Restraints
12.3 Parkinsons Disease Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Parkinsons Disease Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Parkinsons Disease Drug
13.3 Parkinsons Disease Drug Production Process
13.4 Parkinsons Disease Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Parkinsons Disease Drug Typical Distributors
14.3 Parkinsons Disease Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Parkinsons Disease Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Parkinsons Disease Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Teva Basic Information, Manufacturing Base and Competitors
Table 4. Teva Major Business
Table 5. Teva Parkinsons Disease Drug Product and Services
Table 6. Teva Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Teva Recent Developments/Updates
Table 8. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 9. Novartis AG Major Business
Table 10. Novartis AG Parkinsons Disease Drug Product and Services
Table 11. Novartis AG Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Novartis AG Recent Developments/Updates
Table 13. GSK Basic Information, Manufacturing Base and Competitors
Table 14. GSK Major Business
Table 15. GSK Parkinsons Disease Drug Product and Services
Table 16. GSK Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. GSK Recent Developments/Updates
Table 18. AbbVie Basic Information, Manufacturing Base and Competitors
Table 19. AbbVie Major Business
Table 20. AbbVie Parkinsons Disease Drug Product and Services
Table 21. AbbVie Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. AbbVie Recent Developments/Updates
Table 23. Merck Basic Information, Manufacturing Base and Competitors
Table 24. Merck Major Business
Table 25. Merck Parkinsons Disease Drug Product and Services
Table 26. Merck Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Merck Recent Developments/Updates
Table 28. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 29. Boehringer Ingelheim Major Business
Table 30. Boehringer Ingelheim Parkinsons Disease Drug Product and Services
Table 31. Boehringer Ingelheim Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Boehringer Ingelheim Recent Developments/Updates
Table 33. Impax Laboratories Basic Information, Manufacturing Base and Competitors
Table 34. Impax Laboratories Major Business
Table 35. Impax Laboratories Parkinsons Disease Drug Product and Services
Table 36. Impax Laboratories Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Impax Laboratories Recent Developments/Updates
Table 38. Lundbeck Basic Information, Manufacturing Base and Competitors
Table 39. Lundbeck Major Business
Table 40. Lundbeck Parkinsons Disease Drug Product and Services
Table 41. Lundbeck Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Lundbeck Recent Developments/Updates
Table 43. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 44. Sun Pharma Major Business
Table 45. Sun Pharma Parkinsons Disease Drug Product and Services
Table 46. Sun Pharma Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Sun Pharma Recent Developments/Updates
Table 48. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 49. Wockhardt Major Business
Table 50. Wockhardt Parkinsons Disease Drug Product and Services
Table 51. Wockhardt Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Wockhardt Recent Developments/Updates
Table 53. UCB Basic Information, Manufacturing Base and Competitors
Table 54. UCB Major Business
Table 55. UCB Parkinsons Disease Drug Product and Services
Table 56. UCB Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. UCB Recent Developments/Updates
Table 58. Bausch Health Basic Information, Manufacturing Base and Competitors
Table 59. Bausch Health Major Business
Table 60. Bausch Health Parkinsons Disease Drug Product and Services
Table 61. Bausch Health Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Bausch Health Recent Developments/Updates
Table 63. Acadia Basic Information, Manufacturing Base and Competitors
Table 64. Acadia Major Business
Table 65. Acadia Parkinsons Disease Drug Product and Services
Table 66. Acadia Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Acadia Recent Developments/Updates
Table 68. Global Parkinsons Disease Drug Sales Quantity by Manufacturer (2019-2024) & (K Doses)
Table 69. Global Parkinsons Disease Drug Revenue by Manufacturer (2019-2024) & (USD Million)
Table 70. Global Parkinsons Disease Drug Average Price by Manufacturer (2019-2024) & (USD/Dose)
Table 71. Market Position of Manufacturers in Parkinsons Disease Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 72. Head Office and Parkinsons Disease Drug Production Site of Key Manufacturer
Table 73. Parkinsons Disease Drug Market: Company Product Type Footprint
Table 74. Parkinsons Disease Drug Market: Company Product Application Footprint
Table 75. Parkinsons Disease Drug New Market Entrants and Barriers to Market Entry
Table 76. Parkinsons Disease Drug Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Parkinsons Disease Drug Sales Quantity by Region (2019-2024) & (K Doses)
Table 78. Global Parkinsons Disease Drug Sales Quantity by Region (2025-2030) & (K Doses)
Table 79. Global Parkinsons Disease Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 80. Global Parkinsons Disease Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 81. Global Parkinsons Disease Drug Average Price by Region (2019-2024) & (USD/Dose)
Table 82. Global Parkinsons Disease Drug Average Price by Region (2025-2030) & (USD/Dose)
Table 83. Global Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 84. Global Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 85. Global Parkinsons Disease Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 86. Global Parkinsons Disease Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 87. Global Parkinsons Disease Drug Average Price by Type (2019-2024) & (USD/Dose)
Table 88. Global Parkinsons Disease Drug Average Price by Type (2025-2030) & (USD/Dose)
Table 89. Global Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 90. Global Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 91. Global Parkinsons Disease Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 92. Global Parkinsons Disease Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 93. Global Parkinsons Disease Drug Average Price by Application (2019-2024) & (USD/Dose)
Table 94. Global Parkinsons Disease Drug Average Price by Application (2025-2030) & (USD/Dose)
Table 95. North America Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 96. North America Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 97. North America Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 98. North America Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 99. North America Parkinsons Disease Drug Sales Quantity by Country (2019-2024) & (K Doses)
Table 100. North America Parkinsons Disease Drug Sales Quantity by Country (2025-2030) & (K Doses)
Table 101. North America Parkinsons Disease Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 102. North America Parkinsons Disease Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 103. Europe Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 104. Europe Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 105. Europe Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 106. Europe Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 107. Europe Parkinsons Disease Drug Sales Quantity by Country (2019-2024) & (K Doses)
Table 108. Europe Parkinsons Disease Drug Sales Quantity by Country (2025-2030) & (K Doses)
Table 109. Europe Parkinsons Disease Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 110. Europe Parkinsons Disease Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 111. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 112. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 113. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 114. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 115. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Region (2019-2024) & (K Doses)
Table 116. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Region (2025-2030) & (K Doses)
Table 117. Asia-Pacific Parkinsons Disease Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 118. Asia-Pacific Parkinsons Disease Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 119. South America Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 120. South America Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 121. South America Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 122. South America Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 123. South America Parkinsons Disease Drug Sales Quantity by Country (2019-2024) & (K Doses)
Table 124. South America Parkinsons Disease Drug Sales Quantity by Country (2025-2030) & (K Doses)
Table 125. South America Parkinsons Disease Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 126. South America Parkinsons Disease Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 127. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 128. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 129. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 130. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 131. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Region (2019-2024) & (K Doses)
Table 132. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Region (2025-2030) & (K Doses)
Table 133. Middle East & Africa Parkinsons Disease Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 134. Middle East & Africa Parkinsons Disease Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 135. Parkinsons Disease Drug Raw Material
Table 136. Key Manufacturers of Parkinsons Disease Drug Raw Materials
Table 137. Parkinsons Disease Drug Typical Distributors
Table 138. Parkinsons Disease Drug Typical Customers
Table 1. Global Parkinsons Disease Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Parkinsons Disease Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Teva Basic Information, Manufacturing Base and Competitors
Table 4. Teva Major Business
Table 5. Teva Parkinsons Disease Drug Product and Services
Table 6. Teva Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Teva Recent Developments/Updates
Table 8. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 9. Novartis AG Major Business
Table 10. Novartis AG Parkinsons Disease Drug Product and Services
Table 11. Novartis AG Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Novartis AG Recent Developments/Updates
Table 13. GSK Basic Information, Manufacturing Base and Competitors
Table 14. GSK Major Business
Table 15. GSK Parkinsons Disease Drug Product and Services
Table 16. GSK Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. GSK Recent Developments/Updates
Table 18. AbbVie Basic Information, Manufacturing Base and Competitors
Table 19. AbbVie Major Business
Table 20. AbbVie Parkinsons Disease Drug Product and Services
Table 21. AbbVie Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. AbbVie Recent Developments/Updates
Table 23. Merck Basic Information, Manufacturing Base and Competitors
Table 24. Merck Major Business
Table 25. Merck Parkinsons Disease Drug Product and Services
Table 26. Merck Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Merck Recent Developments/Updates
Table 28. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 29. Boehringer Ingelheim Major Business
Table 30. Boehringer Ingelheim Parkinsons Disease Drug Product and Services
Table 31. Boehringer Ingelheim Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Boehringer Ingelheim Recent Developments/Updates
Table 33. Impax Laboratories Basic Information, Manufacturing Base and Competitors
Table 34. Impax Laboratories Major Business
Table 35. Impax Laboratories Parkinsons Disease Drug Product and Services
Table 36. Impax Laboratories Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Impax Laboratories Recent Developments/Updates
Table 38. Lundbeck Basic Information, Manufacturing Base and Competitors
Table 39. Lundbeck Major Business
Table 40. Lundbeck Parkinsons Disease Drug Product and Services
Table 41. Lundbeck Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Lundbeck Recent Developments/Updates
Table 43. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 44. Sun Pharma Major Business
Table 45. Sun Pharma Parkinsons Disease Drug Product and Services
Table 46. Sun Pharma Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Sun Pharma Recent Developments/Updates
Table 48. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 49. Wockhardt Major Business
Table 50. Wockhardt Parkinsons Disease Drug Product and Services
Table 51. Wockhardt Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Wockhardt Recent Developments/Updates
Table 53. UCB Basic Information, Manufacturing Base and Competitors
Table 54. UCB Major Business
Table 55. UCB Parkinsons Disease Drug Product and Services
Table 56. UCB Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. UCB Recent Developments/Updates
Table 58. Bausch Health Basic Information, Manufacturing Base and Competitors
Table 59. Bausch Health Major Business
Table 60. Bausch Health Parkinsons Disease Drug Product and Services
Table 61. Bausch Health Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Bausch Health Recent Developments/Updates
Table 63. Acadia Basic Information, Manufacturing Base and Competitors
Table 64. Acadia Major Business
Table 65. Acadia Parkinsons Disease Drug Product and Services
Table 66. Acadia Parkinsons Disease Drug Sales Quantity (K Doses), Average Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Acadia Recent Developments/Updates
Table 68. Global Parkinsons Disease Drug Sales Quantity by Manufacturer (2019-2024) & (K Doses)
Table 69. Global Parkinsons Disease Drug Revenue by Manufacturer (2019-2024) & (USD Million)
Table 70. Global Parkinsons Disease Drug Average Price by Manufacturer (2019-2024) & (USD/Dose)
Table 71. Market Position of Manufacturers in Parkinsons Disease Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 72. Head Office and Parkinsons Disease Drug Production Site of Key Manufacturer
Table 73. Parkinsons Disease Drug Market: Company Product Type Footprint
Table 74. Parkinsons Disease Drug Market: Company Product Application Footprint
Table 75. Parkinsons Disease Drug New Market Entrants and Barriers to Market Entry
Table 76. Parkinsons Disease Drug Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Parkinsons Disease Drug Sales Quantity by Region (2019-2024) & (K Doses)
Table 78. Global Parkinsons Disease Drug Sales Quantity by Region (2025-2030) & (K Doses)
Table 79. Global Parkinsons Disease Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 80. Global Parkinsons Disease Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 81. Global Parkinsons Disease Drug Average Price by Region (2019-2024) & (USD/Dose)
Table 82. Global Parkinsons Disease Drug Average Price by Region (2025-2030) & (USD/Dose)
Table 83. Global Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 84. Global Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 85. Global Parkinsons Disease Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 86. Global Parkinsons Disease Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 87. Global Parkinsons Disease Drug Average Price by Type (2019-2024) & (USD/Dose)
Table 88. Global Parkinsons Disease Drug Average Price by Type (2025-2030) & (USD/Dose)
Table 89. Global Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 90. Global Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 91. Global Parkinsons Disease Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 92. Global Parkinsons Disease Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 93. Global Parkinsons Disease Drug Average Price by Application (2019-2024) & (USD/Dose)
Table 94. Global Parkinsons Disease Drug Average Price by Application (2025-2030) & (USD/Dose)
Table 95. North America Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 96. North America Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 97. North America Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 98. North America Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 99. North America Parkinsons Disease Drug Sales Quantity by Country (2019-2024) & (K Doses)
Table 100. North America Parkinsons Disease Drug Sales Quantity by Country (2025-2030) & (K Doses)
Table 101. North America Parkinsons Disease Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 102. North America Parkinsons Disease Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 103. Europe Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 104. Europe Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 105. Europe Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 106. Europe Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 107. Europe Parkinsons Disease Drug Sales Quantity by Country (2019-2024) & (K Doses)
Table 108. Europe Parkinsons Disease Drug Sales Quantity by Country (2025-2030) & (K Doses)
Table 109. Europe Parkinsons Disease Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 110. Europe Parkinsons Disease Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 111. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 112. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 113. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 114. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 115. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Region (2019-2024) & (K Doses)
Table 116. Asia-Pacific Parkinsons Disease Drug Sales Quantity by Region (2025-2030) & (K Doses)
Table 117. Asia-Pacific Parkinsons Disease Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 118. Asia-Pacific Parkinsons Disease Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 119. South America Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 120. South America Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 121. South America Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 122. South America Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 123. South America Parkinsons Disease Drug Sales Quantity by Country (2019-2024) & (K Doses)
Table 124. South America Parkinsons Disease Drug Sales Quantity by Country (2025-2030) & (K Doses)
Table 125. South America Parkinsons Disease Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 126. South America Parkinsons Disease Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 127. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Type (2019-2024) & (K Doses)
Table 128. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Type (2025-2030) & (K Doses)
Table 129. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Application (2019-2024) & (K Doses)
Table 130. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Application (2025-2030) & (K Doses)
Table 131. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Region (2019-2024) & (K Doses)
Table 132. Middle East & Africa Parkinsons Disease Drug Sales Quantity by Region (2025-2030) & (K Doses)
Table 133. Middle East & Africa Parkinsons Disease Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 134. Middle East & Africa Parkinsons Disease Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 135. Parkinsons Disease Drug Raw Material
Table 136. Key Manufacturers of Parkinsons Disease Drug Raw Materials
Table 137. Parkinsons Disease Drug Typical Distributors
Table 138. Parkinsons Disease Drug Typical Customers
LIST OF FIGURES
Figure 1. Parkinsons Disease Drug Picture
Figure 2. Global Parkinsons Disease Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Parkinsons Disease Drug Consumption Value Market Share by Type in 2023
Figure 4. Carbidopa/Levodopa Examples
Figure 5. Dopamine Receptor Agonists Examples
Figure 6. MAO-Inhibitors Examples
Figure 7. Global Parkinsons Disease Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Parkinsons Disease Drug Consumption Value Market Share by Application in 2023
Figure 9. Hospital Examples
Figure 10. Clinics Examples
Figure 11. Other Examples
Figure 12. Global Parkinsons Disease Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Parkinsons Disease Drug Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Parkinsons Disease Drug Sales Quantity (2019-2030) & (K Doses)
Figure 15. Global Parkinsons Disease Drug Average Price (2019-2030) & (USD/Dose)
Figure 16. Global Parkinsons Disease Drug Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Parkinsons Disease Drug Consumption Value Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Parkinsons Disease Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 19. Top 3 Parkinsons Disease Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Top 6 Parkinsons Disease Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Global Parkinsons Disease Drug Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Parkinsons Disease Drug Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Parkinsons Disease Drug Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Parkinsons Disease Drug Average Price by Type (2019-2030) & (USD/Dose)
Figure 31. Global Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Parkinsons Disease Drug Consumption Value Market Share by Application (2019-2030)
Figure 33. Global Parkinsons Disease Drug Average Price by Application (2019-2030) & (USD/Dose)
Figure 34. North America Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Parkinsons Disease Drug Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Parkinsons Disease Drug Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Canada Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Mexico Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Europe Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Parkinsons Disease Drug Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Parkinsons Disease Drug Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. France Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. United Kingdom Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Russia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Italy Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Parkinsons Disease Drug Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Parkinsons Disease Drug Consumption Value Market Share by Region (2019-2030)
Figure 54. China Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Japan Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Korea Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. India Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Southeast Asia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Australia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. South America Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Parkinsons Disease Drug Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Parkinsons Disease Drug Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Argentina Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Parkinsons Disease Drug Sales Quantity Market Share by Region (2019-2030)
Figure 69. Middle East & Africa Parkinsons Disease Drug Consumption Value Market Share by Region (2019-2030)
Figure 70. Turkey Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Egypt Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. South Africa Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Parkinsons Disease Drug Market Drivers
Figure 75. Parkinsons Disease Drug Market Restraints
Figure 76. Parkinsons Disease Drug Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Parkinsons Disease Drug in 2023
Figure 79. Manufacturing Process Analysis of Parkinsons Disease Drug
Figure 80. Parkinsons Disease Drug Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. Parkinsons Disease Drug Picture
Figure 2. Global Parkinsons Disease Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Parkinsons Disease Drug Consumption Value Market Share by Type in 2023
Figure 4. Carbidopa/Levodopa Examples
Figure 5. Dopamine Receptor Agonists Examples
Figure 6. MAO-Inhibitors Examples
Figure 7. Global Parkinsons Disease Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Parkinsons Disease Drug Consumption Value Market Share by Application in 2023
Figure 9. Hospital Examples
Figure 10. Clinics Examples
Figure 11. Other Examples
Figure 12. Global Parkinsons Disease Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Parkinsons Disease Drug Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Parkinsons Disease Drug Sales Quantity (2019-2030) & (K Doses)
Figure 15. Global Parkinsons Disease Drug Average Price (2019-2030) & (USD/Dose)
Figure 16. Global Parkinsons Disease Drug Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Parkinsons Disease Drug Consumption Value Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Parkinsons Disease Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 19. Top 3 Parkinsons Disease Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Top 6 Parkinsons Disease Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Global Parkinsons Disease Drug Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Parkinsons Disease Drug Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Parkinsons Disease Drug Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Parkinsons Disease Drug Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Parkinsons Disease Drug Average Price by Type (2019-2030) & (USD/Dose)
Figure 31. Global Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Parkinsons Disease Drug Consumption Value Market Share by Application (2019-2030)
Figure 33. Global Parkinsons Disease Drug Average Price by Application (2019-2030) & (USD/Dose)
Figure 34. North America Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Parkinsons Disease Drug Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Parkinsons Disease Drug Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Canada Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Mexico Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Europe Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Parkinsons Disease Drug Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Parkinsons Disease Drug Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. France Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. United Kingdom Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Russia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Italy Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Parkinsons Disease Drug Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Parkinsons Disease Drug Consumption Value Market Share by Region (2019-2030)
Figure 54. China Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Japan Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Korea Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. India Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Southeast Asia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Australia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. South America Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Parkinsons Disease Drug Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Parkinsons Disease Drug Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Argentina Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Parkinsons Disease Drug Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Parkinsons Disease Drug Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Parkinsons Disease Drug Sales Quantity Market Share by Region (2019-2030)
Figure 69. Middle East & Africa Parkinsons Disease Drug Consumption Value Market Share by Region (2019-2030)
Figure 70. Turkey Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Egypt Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. South Africa Parkinsons Disease Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Parkinsons Disease Drug Market Drivers
Figure 75. Parkinsons Disease Drug Market Restraints
Figure 76. Parkinsons Disease Drug Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Parkinsons Disease Drug in 2023
Figure 79. Manufacturing Process Analysis of Parkinsons Disease Drug
Figure 80. Parkinsons Disease Drug Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
